CXCR4 and CXCL12 expression in rectal tumors of stage IV patients before and after local radiotherapy and systemic neoadjuvant treatment

Current Pharmaceutical Design

Volumn 21, Issue 17, 2015, Pages 2276-2283

  Tamas, Karin ^a   Domanska, Urszula M ^a,b   van Dijk, Tonnis H ^a   Timmer Bosscha, Hetty ^a   Havenga, Klaas ^a   Karrenbeld, Arend ^a   Sluiter, Wim J ^a   Beukema, Jannet C ^a   van Vugt, Marcel A T M ^a   de Vries, Elisabeth G E ^a   Hospers, Geke A P ^a   Walenkamp, Annemiek M E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

(Metastatic) rectal cancer; Bevacizumab; Chemokine ligand 12 (CXCL12); Chemokine receptor 4 (CXCR4); Chemotherapy; Radiotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CHEMOKINE RECEPTOR CXCR4; OXALIPLATIN; STROMAL CELL DERIVED FACTOR 1; ANTINEOPLASTIC AGENT; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL NUCLEUS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPT CELL; CYTOPLASM; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM TUMOR; TREATMENT RESPONSE; TUMOR CELL; UPREGULATION; BIOSYNTHESIS; CANCER STAGING; METABOLISM; NEOADJUVANT THERAPY; PATHOLOGY; RECTAL NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOKINE CXCL12; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTORS, CXCR4; RECTAL NEOPLASMS;

EID: 84929484187     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150105155615     Document Type: Article

References (41)

1. De Caluwe L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013; 2: CD006041.
2. Gérard J, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006; 24: 4620-5.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
4. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-705.
5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007; 25: 1539-44.
6. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-34.
7. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of firstline bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009; 20: 1842-7.
8. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
9. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
10. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37.
11. Van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of shortcourse radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013; 24: 1762-9.
12. Czito BG, Bendell JC, Willett CG, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 2007; 68: 472-8.
13. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
14. Yoshitake N, Fukui H, Yamagishi H, et al. Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer 2008; 98: 1682-9.
15. Wang SC, Lin JK, Wang HS, Yang SH, Li AF, Chang SC. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis 2010; 25: 1185-91.
16. Heckmann D, Maier P, Laufs S, et al. The disparate twins: A comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer. Clin Cancer Res 2014; 20: 604-16.
17. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer 2013; 49: 219-30.
18. Kollmar O, Rupertus K, Scheuer C, et al. Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 2007; 9: 862-70.
19. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003; 63: 3833-9.
20. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120: 694-705.
21. Ou D, Chen C, Lin S, Hsu C, Lin L. Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J Pathol 2006; 210: 363-73.
22. Xu L, Duda DG, Di Tomaso E, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1α, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009; 69: 7905-10.
23. Greene FL, Fleming ID, Fritz AG, et al. AJCC cancer staging manual. 6th ed. New York (NY): Springer 2002; pp 113-123.
24. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50, 042 patients. Ann Surg 2002; 236: 416-21.
25. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-6.
26. Guedj N, Bretagnol F, Rautou P, et al. Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Hum Pathol 2011; 42: 1702-9.
27. Di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapy in patients: Lack of “rebound” revascularization as mode of escape. Cancer Res 2011; 71: 19-28.
28. Zagzag D, Krishnamachary B, Yee H, et al. Stromal cell-derived factor-1[1] and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: Von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65: 6178-88.
29. Boivin B, Vaniotis G, Allen BG, Hebert TE. G protein-coupled receptors in and on the cell nucleus: A new signaling paradigm? J Recept Signal Transduct Res 2008; 28: 15-28.
30. Tadevosyan A, Vaniotis G, Allen BG, Hebert TE, Nattel S. G protein- coupled receptor signalling in the cardiac nuclear membrane: Evidence and possible roles in physiological and pathophysiological function. J Physiol 2012; 590: 1313-30.
31. Saigusa S, Toiyama Y, Tanaka K, et al. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol 2010; 17: 2051-8.
32. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23: 2744-53.
33. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapyinduced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14: 263-73.
34. Lerman OZ, Greives MR, Singh SP, et al. Low-dose radiation augments vasculogenesis signaling through HIF-1–dependent and – independent SDF-1 induction. Blood 2010; 116: 3669-76.
35. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-64.
36. Zhu D, Keohavong P, Finkelstein SD, et al. K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res 1997; 57: 2485-92.
37. Jain RK. Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol 2013; 31: 2205-18.
38. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008; 25: 201-11.
39. Wong D, Kandagatla P, Korz W, Chinni SR. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol 2014. doi: 10.1186/1471-2490-14-12.
40. Hotte SJ, Hirte HW, Moretto P, et al. Final results of a phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. Eur J Cancer 2008; 6: 127 (abstract).
41. Galsky MD, Vogelzang NJ, Conkling P, et al. Phase I Trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res 2014; 20: 3581-8.